GLP1R and obesity due to melanocortin 4 receptor deficiency: Glucagon-like peptide-1 receptor (GLP-1R) agonists are widely used in clinical practice as therapy for type 2 diabetes and obesity and one of its beneficial effects is that it induces a negative energy balance by decreasing appetite.